Hematology 2025_ Event Postponement

This is to inform that due to some circumstances beyond the organizer control, "2nd Edition of International Summit on Hematology and Blood Disorders" (Hematology 2025) June 05-07, 2025 | Hybrid Event has been postponed. The updated dates and venue will be displayed shortly.

Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.

For further details, please contact us at hematology@magnusconference.com or call + 1 (702) 988 2320.

Rare Hematologic Diseases

A rare disease in the United States is one that affects fewer than 200,000 people in the country. Congress established this definition in the Orphan Drug Act of 1983. Because pharma corporations were not interested in developing medicines for rare diseases, they became known as orphan diseases. The Orphan Drug Act established financial incentives for companies to discover new medicines for uncommon diseases. The definition of rare disease was required in order to determine which disorders would be eligible for the new incentive programmes. Certain cell types can be created in abnormally large quantities or in atypical forms when the usual process of blood cell growth and development breaks down. Blood malignancies and other blood problems arise as a result of this.